NT-CoV-2 (Terra CoV-2)
Prevention of COVID-19 and SARS-CoV-2 variants
PreclinicalCandidate in development
Key Facts
Indication
Prevention of COVID-19 and SARS-CoV-2 variants
Phase
Preclinical
Status
Candidate in development
Company
About Oragenics
Oragenics is striving to revolutionize neurological care through its proprietary intranasal delivery technology, which bypasses the blood-brain barrier to enable targeted, non-invasive brain therapeutics. The company's lead program, ONP-002, has completed Phase 1 safety studies for concussion and is preparing for Phase 2, with a broader pipeline including ONP-001 for rare leukodystrophies and a vaccine program. Oragenics is a public company (NYSE American: OGEN) positioning itself at the intersection of neurology and innovative drug delivery.
View full company profile